154 related articles for article (PubMed ID: 31173649)
1. Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention.
Whalen ME; Kajubi R; Chamankhah N; Huang L; Orukan F; Wallender E; Kamya MR; Dorsey G; Jagannathan P; Rosenthal PJ; Mwebaza N; Aweeka FT
Clin Pharmacol Ther; 2019 Dec; 106(6):1310-1318. PubMed ID: 31173649
[TBL] [Abstract][Full Text] [Related]
2. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children.
Sundell K; Jagannathan P; Huang L; Bigira V; Kapisi J; Kakuru MM; Savic R; Kamya MR; Dorsey G; Aweeka F
Malar J; 2015 Sep; 14():368. PubMed ID: 26403465
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine.
Permala J; Tarning J; Nosten F; White NJ; Karlsson MO; Bergstrand M
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242661
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention.
Kajubi R; Huang L; Jagannathan P; Chamankhah N; Were M; Ruel T; Koss CA; Kakuru A; Mwebaza N; Kamya M; Havlir D; Dorsey G; Rosenthal PJ; Aweeka FT
Clin Pharmacol Ther; 2017 Sep; 102(3):520-528. PubMed ID: 28187497
[TBL] [Abstract][Full Text] [Related]
5. Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.
Wallender E; Zhang N; Conrad M; Kakuru A; Muhindo M; Tumwebaze P; Kajubi R; Mota D; Legac J; Jagannathan P; Havlir D; Kamya M; Dorsey G; Aweeka F; Rosenthal PJ; Savic RM
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530597
[TBL] [Abstract][Full Text] [Related]
6. Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial.
Muhindo MK; Jagannathan P; Kakuru A; Opira B; Olwoch P; Okiring J; Nalugo N; Clark TD; Ruel T; Charlebois E; Feeney ME; Havlir DV; Dorsey G; Kamya MR
Lancet Infect Dis; 2019 Sep; 19(9):962-972. PubMed ID: 31307883
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria.
Rijken MJ; McGready R; Phyo AP; Lindegardh N; Tarning J; Laochan N; Than HH; Mu O; Win AK; Singhasivanon P; White N; Nosten F
Antimicrob Agents Chemother; 2011 Dec; 55(12):5500-6. PubMed ID: 21947392
[TBL] [Abstract][Full Text] [Related]
8. Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children.
Chotsiri P; Zongo I; Milligan P; Compaore YD; Somé AF; Chandramohan D; Hanpithakpong W; Nosten F; Greenwood B; Rosenthal PJ; White NJ; Ouédraogo JB; Tarning J
Nat Commun; 2019 Jan; 10(1):480. PubMed ID: 30696903
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
Nguyen DV; Nguyen QP; Nguyen ND; Le TT; Nguyen TD; Dinh DN; Nguyen TX; Bui D; Chavchich M; Edstein MD
Antimicrob Agents Chemother; 2009 Aug; 53(8):3534-7. PubMed ID: 19528277
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
Tarning J; Ashley EA; Lindegardh N; Stepniewska K; Phaiphun L; Day NP; McGready R; Ashton M; Nosten F; White NJ
Antimicrob Agents Chemother; 2008 Mar; 52(3):1052-61. PubMed ID: 18180343
[TBL] [Abstract][Full Text] [Related]
11. Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children.
Wallender E; Ali AM; Hughes E; Kakuru A; Jagannathan P; Muhindo MK; Opira B; Whalen M; Huang L; Duvalsaint M; Legac J; Kamya MR; Dorsey G; Aweeka F; Rosenthal PJ; Savic RM
Nat Commun; 2021 Nov; 12(1):6714. PubMed ID: 34795281
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria.
Lwin KM; Phyo AP; Tarning J; Hanpithakpong W; Ashley EA; Lee SJ; Cheah P; Singhasivanon P; White NJ; Lindegårdh N; Nosten F
Antimicrob Agents Chemother; 2012 Mar; 56(3):1571-7. PubMed ID: 22252804
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.
Sambol NC; Yan L; Creek DJ; McCormack SA; Arinaitwe E; Bigira V; Wanzira H; Kakuru A; Tappero JW; Lindegardh N; Tarning J; Nosten F; Aweeka FT; Parikh S
Clin Pharmacol Ther; 2015 Jul; 98(1):87-95. PubMed ID: 25732044
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.
Benjamin JM; Moore BR; Salman S; Page-Sharp M; Tawat S; Yadi G; Lorry L; Siba PM; Batty KT; Robinson LJ; Mueller I; Davis TM
Antimicrob Agents Chemother; 2015 Jul; 59(7):4260-71. PubMed ID: 25963981
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants.
Creek DJ; Bigira V; McCormack S; Arinaitwe E; Wanzira H; Kakuru A; Tappero JW; Sandison TG; Lindegardh N; Nosten F; Aweeka FT; Parikh S
J Infect Dis; 2013 Jun; 207(11):1646-54. PubMed ID: 23447696
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria.
Price RN; Hasugian AR; Ratcliff A; Siswantoro H; Purba HL; Kenangalem E; Lindegardh N; Penttinen P; Laihad F; Ebsworth EP; Anstey NM; Tjitra E
Antimicrob Agents Chemother; 2007 Nov; 51(11):4090-7. PubMed ID: 17846129
[TBL] [Abstract][Full Text] [Related]
17. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial.
Tran TH; Dolecek C; Pham PM; Nguyen TD; Nguyen TT; Le HT; Dong TH; Tran TT; Stepniewska K; White NJ; Farrar J
Lancet; 2004 Jan; 363(9402):18-22. PubMed ID: 14723988
[TBL] [Abstract][Full Text] [Related]
18. Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine.
Byakika-Kibwika P; Ssenyonga R; Lamorde M; Blessborn D; Tarning J
BMC Infect Dis; 2019 Dec; 19(1):1025. PubMed ID: 31795967
[TBL] [Abstract][Full Text] [Related]
19. Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study.
Sambol NC; Tappero JW; Arinaitwe E; Parikh S
PLoS One; 2016; 11(5):e0154623. PubMed ID: 27182702
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali.
Dama S; Niangaly H; Djimde M; Sagara I; Guindo CO; Zeguime A; Dara A; Djimde AA; Doumbo OK
Malar J; 2018 Oct; 17(1):347. PubMed ID: 30290808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
